-
1
-
-
82955189267
-
Prognostic relevance of 18-FFDGPET-CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
-
Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-FFDGPET-CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989-5995.
-
(2011)
Blood
, vol.118
, Issue.23
, pp. 5989-5995
-
-
Zamagni, E.1
Patriarca, F.2
Nanni, C.3
-
2
-
-
70349231349
-
F18-fluorode-oxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
-
Bartel TB, Haessler J, Brown TL, et al. F18-fluorode-oxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068-2076.
-
(2009)
Blood
, vol.114
, Issue.10
, pp. 2068-2076
-
-
Bartel, T.B.1
Haessler, J.2
Brown, T.L.3
-
3
-
-
79955977910
-
Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1
-
Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695.
-
(2011)
Blood
, vol.117
, Issue.18
, pp. 4691-4695
-
-
Rajkumar, S.V.1
Harousseau, J.L.2
Durie, B.3
-
4
-
-
59449099316
-
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
-
Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-4023.
-
(2008)
Blood
, vol.112
, Issue.10
, pp. 4017-4023
-
-
Paiva, B.1
Vidriales, M.B.2
Cervero, J.3
-
5
-
-
77951625298
-
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
-
Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28(12):2077-2084.
-
(2010)
J Clin Oncol
, vol.28
, Issue.12
, pp. 2077-2084
-
-
Ladetto, M.1
Pagliano, G.2
Ferrero, S.3
-
6
-
-
79956001465
-
Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3
-
Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117(18):4701-4705.
-
(2011)
Blood
, vol.117
, Issue.18
, pp. 4701-4705
-
-
Dimopoulos, M.1
Kyle, R.2
Fermand, J.P.3
-
7
-
-
80053621178
-
Soft-tissue plasmacytomas in multiple myeloma: Incidence, mechanisms of extramedullary spread, and treatment approach
-
Bladé J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805-3812.
-
(2011)
J Clin Oncol
, vol.29
, Issue.28
, pp. 3805-3812
-
-
Bladé, J.1
Fernandez De Larrea, C.2
Rosinol, L.3
Cibeira, M.T.4
Jimenez, R.5
Powles, R.6
-
8
-
-
33947496614
-
Revised response criteria for malignant lymphoma
-
DOI 10.1200/JCO.2006.09.2403
-
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.5
, pp. 579-586
-
-
Cheson, B.D.1
Pfistner, B.2
Juweid, M.E.3
Gascoyne, R.D.4
Specht, L.5
Horning, S.J.6
Coiffier, B.7
Fisher, R.I.8
Hagenbeek, A.9
Zucca, E.10
Rosen, S.T.11
Stroobants, S.12
Lister, T.A.13
Hoppe, R.T.14
Dreyling, M.15
Tobinai, K.16
Vose, J.M.17
Connors, J.M.18
Federico, M.19
Diehl, V.20
more..
|